{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T05:13:46Z","timestamp":1788930826474,"version":"build-2803163510"},"reference-count":34,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,8]],"date-time":"2024-04-08T00:00:00Z","timestamp":1712534400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009857","name":"Regeneron Pharmaceuticals Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009857","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004339","name":"Sanofi US","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jaadinternational.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JAAD International"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.jdin.2024.03.025","type":"journal-article","created":{"date-parts":[[2024,4,10]],"date-time":"2024-04-10T03:23:32Z","timestamp":1712719412000},"page":"163-174","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"special_numbering":"C","title":["Dupilumab improves pruritus and skin lesions in patients with prurigo nodularis: Pooled results from 2 phase 3 trials (LIBERTY-PN PRIME and PRIME2)"],"prefix":"10.1016","volume":"16","author":[{"given":"Gil","family":"Yosipovitch","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian S.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shawn G.","family":"Kwatra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas K.","family":"Mollanazar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonja","family":"St\u00e4nder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Satoh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro","family":"Mendes-Bastos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsen-Fang","family":"Tsai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Laws","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael C.","family":"Nivens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Maloney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Genming","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashish","family":"Bansal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ariane","family":"Dubost-Brama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.jdin.2024.03.025_bib1","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1111\/ced.14722","article-title":"Clinical characteristics and disease burden in prurigo nodularis","volume":"46","author":"Aggarwal","year":"2021","journal-title":"Clin Exp Dermatol"},{"issue":"3","key":"10.1016\/j.jdin.2024.03.025_bib2","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/j.jaad.2020.07.025","article-title":"Practical approaches for diagnosis and management of prurigo nodularis: United States expert panel consensus","volume":"84","author":"Elmariah","year":"2021","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"10.1016\/j.jdin.2024.03.025_bib3","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.jaad.2021.05.036","article-title":"Health-related quality of life and economic burden of prurigo nodularis","volume":"86","author":"Whang","year":"2022","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"10.1016\/j.jdin.2024.03.025_bib4","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.jaad.2018.04.044","article-title":"Humanistic burden of chronic pruritus in patients with inflammatory dermatoses: results of the European Academy of Dermatology and Venereology network on assessment of severity and burden of pruritus (PruNet) cross-sectional trial","volume":"79","author":"Steinke","year":"2018","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"10.1016\/j.jdin.2024.03.025_bib5","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1111\/jdv.16929","article-title":"The burden in chronic prurigo: patients with chronic prurigo suffer more than patients with chronic pruritus on non-lesional skin: a comparative, retrospective, explorative statistical analysis of 4,484 patients in a real-world cohort","volume":"35","author":"Zeidler","year":"2021","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"10","key":"10.1016\/j.jdin.2024.03.025_bib6","doi-asserted-by":"crossref","first-page":"2530","DOI":"10.1016\/j.jid.2021.02.756","article-title":"A nationwide study of prurigo nodularis: disease burden and healthcare utilization in the United States","volume":"141","author":"Wongvibulsin","year":"2021","journal-title":"J Invest Dermatol"},{"issue":"1","key":"10.1016\/j.jdin.2024.03.025_bib7","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1080\/17512433.2021.1852080","article-title":"Pathophysiology, diagnosis, and pharmacological treatment of prurigo nodularis","volume":"14","author":"Williams","year":"2021","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"3","key":"10.1016\/j.jdin.2024.03.025_bib8","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1016\/j.jaad.2018.09.020","article-title":"A systematic review of evidence-based treatments for prurigo nodularis","volume":"80","author":"Qureshi","year":"2019","journal-title":"J Am Acad Dermatol"},{"issue":"14","key":"10.1016\/j.jdin.2024.03.025_bib10","doi-asserted-by":"crossref","first-page":"5147","DOI":"10.1073\/pnas.1323896111","article-title":"Precise and in situ genetic humanization of 6 Mb of mouse immunoglobulin genes","volume":"111","author":"Macdonald","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"14","key":"10.1016\/j.jdin.2024.03.025_bib11","doi-asserted-by":"crossref","first-page":"5153","DOI":"10.1073\/pnas.1324022111","article-title":"Mice with megabase humanization of their immunoglobulin genes generate antibodies as efficiently as normal mice","volume":"111","author":"Murphy","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"5","key":"10.1016\/j.jdin.2024.03.025_bib12","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1038\/s41591-023-02320-9","article-title":"Dupilumab in patients with prurigo nodularis: two randomized, double-blind, placebo-controlled phase 3 trials","volume":"29","author":"Yosipovitch","year":"2023","journal-title":"Nat Med"},{"issue":"4","key":"10.1016\/j.jdin.2024.03.025_bib13","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1111\/jdv.17870","article-title":"Worst itch numerical rating scale for prurigo nodularis: a psychometric evaluation","volume":"36","author":"St\u00e4nder","year":"2022","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"13","key":"10.1016\/j.jdin.2024.03.025_bib14","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.2340\/00015555-3332","article-title":"Minimal clinically important difference in chronic pruritus appears to be dependent on baseline itch severity","volume":"99","author":"Riepe","year":"2019","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.jdin.2024.03.025_bib15","doi-asserted-by":"crossref","unstructured":"Bahloul D, Thomas RB, Rhoten S, et al. Validation of the Worst-Itch Numeric Rating Scale (WI-NRS) in prurigo nodularis (PN) based on clinical studies of dupilumab in adults with PN. Poster presented at AAD 2023. March 17-21, New Orleans, LA.","DOI":"10.1016\/j.jaad.2023.07.417"},{"issue":"2","key":"10.1016\/j.jdin.2024.03.025_bib16","doi-asserted-by":"crossref","DOI":"10.2340\/00015555-3701","article-title":"Investigator's global assessment of chronic prurigo: a new instrument for use in clinical trials","volume":"101","author":"Zeidler","year":"2021","journal-title":"Acta Derm Venereol"},{"issue":"4","key":"10.1016\/j.jdin.2024.03.025_bib17","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1016\/j.jaad.2018.04.047","article-title":"Ethnic differences and comorbidities of 909 prurigo nodularis patients","volume":"79","author":"Boozalis","year":"2018","journal-title":"J Am Acad Dematol"},{"issue":"1","key":"10.1016\/j.jdin.2024.03.025_bib18","doi-asserted-by":"crossref","first-page":"95","DOI":"10.3390\/jcm11010095","article-title":"Epidemiology, comorbidities, and prescription patterns of Korean prurigo nodularis patients: a multi-institution study","volume":"11","author":"Woo","year":"2021","journal-title":"J Clin Med"},{"issue":"3","key":"10.1016\/j.jdin.2024.03.025_bib19","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1001\/jamadermatol.2021.5307","article-title":"Prurigo nodularis","volume":"158","author":"Kwatra","year":"2022","journal-title":"JAMA Dermatol"},{"issue":"9","key":"10.1016\/j.jdin.2024.03.025_bib20","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1016\/j.jid.2022.02.010","article-title":"Cutaneous transcriptomic identifies fibroproliferative and neurovascular gene dysregulation in prurigo nodularis compared with psoriasis and atopic dermatitis","volume":"142","author":"Sutaria","year":"2022","journal-title":"J Invest Dermatol"},{"issue":"12","key":"10.1016\/j.jdin.2024.03.025_bib21","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1016\/j.jid.2023.04.033","article-title":"A polygenic risk score for predicting racial and genetic susceptibility to prurigo nodularis","volume":"143","author":"Vasavda","year":"2023","journal-title":"J Invest Dermatol"},{"issue":"2","key":"10.1016\/j.jdin.2024.03.025_bib22","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1056\/NEJMoa1314768","article-title":"Dupilumab treatment in adults with moderate-to-severe atopic dermatitis","volume":"371","author":"Beck","year":"2014","journal-title":"N Engl J Med"},{"issue":"10086","key":"10.1016\/j.jdin.2024.03.025_bib23","doi-asserted-by":"crossref","first-page":"2287","DOI":"10.1016\/S0140-6736(17)31191-1","article-title":"Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial","volume":"389","author":"Blauvelt","year":"2017","journal-title":"Lancet"},{"issue":"10209","key":"10.1016\/j.jdin.2024.03.025_bib24","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1016\/S0140-6736(19)31881-1","article-title":"Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials","volume":"394","author":"Bachert","year":"2019","journal-title":"Lancet"},{"issue":"26","key":"10.1016\/j.jdin.2024.03.025_bib25","doi-asserted-by":"crossref","first-page":"2475","DOI":"10.1056\/NEJMoa1804093","article-title":"Efficacy and safety of dupilumab in glucocorticoid-dependent severe asthma","volume":"378","author":"Rabe","year":"2018","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.jdin.2024.03.025_bib26","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1111\/bjd.17869","article-title":"Conjunctivitis in dupilumab clinical trials","volume":"181","author":"Akinlade","year":"2019","journal-title":"Br J Dermatol"},{"issue":"3","key":"10.1016\/j.jdin.2024.03.025_bib27","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1007\/s40257-019-00445-7","article-title":"Infections in dupilumab clinical trials in atopic dermatitis: a comprehensive pooled analysis","volume":"20","author":"Eichenfield","year":"2019","journal-title":"Am J Clin Dermatol"},{"issue":"1","key":"10.1016\/j.jdin.2024.03.025_bib28","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1007\/s12325-022-02322-y","article-title":"No increased risk in overall infection in adults with moderate-to-severe atopic dermatitis treated for up to 4 years with dupilumab","volume":"40","author":"Blauvelt","year":"2023","journal-title":"Adv Ther"},{"issue":"2","key":"10.1016\/j.jdin.2024.03.025_bib29","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/pde.14909","article-title":"Infections in children and adolescents treated with dupilumab in pediatric clinical trials for atopic dermatitis \u2013 a pooled analysis of trial data","volume":"39","author":"Paller","year":"2022","journal-title":"Pediatr Dermatol"},{"issue":"6","key":"10.1016\/j.jdin.2024.03.025_bib30","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1016\/j.jaad.2020.02.060","article-title":"Dupilumab treatment results in early and sustained improvements in itch in adolescents and adults with moderate to severe atopic dermatitis: analysis of the randomized phase 3 studies SOLO 1 and SOLO 2, AD ADOL, and CHRONOS","volume":"82","author":"Silverberg","year":"2020","journal-title":"J Am Acad Dermatol"},{"issue":"11","key":"10.1016\/j.jdin.2024.03.025_bib31","doi-asserted-by":"crossref","first-page":"3388","DOI":"10.1111\/all.15432","article-title":"Dupilumab significantly improves skin barrier function in patients with moderate-to-severe atopic dermatitis","volume":"77","author":"Berdyshev","year":"2022","journal-title":"Allergy"},{"issue":"3","key":"10.1016\/j.jdin.2024.03.025_bib32","doi-asserted-by":"crossref","first-page":"303","DOI":"10.3390\/vaccines9030303","article-title":"Pruritus as a distinctive feature of type 2 inflammation","volume":"9","author":"Garcovich","year":"2021","journal-title":"Vaccines (Basel)"},{"issue":"1","key":"10.1016\/j.jdin.2024.03.025_bib33","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.cell.2017.08.006","article-title":"Sensory neurons co-opt classical immune signaling pathways to mediate chronic itch","volume":"171","author":"Oetjen","year":"2017","journal-title":"Cell"},{"issue":"5","key":"10.1016\/j.jdin.2024.03.025_bib34","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/j.immuni.2020.04.008","article-title":"Itch: a paradigm of neuroimmune crosstalk","volume":"52","author":"Wang","year":"2020","journal-title":"Immunity"},{"key":"10.1016\/j.jdin.2024.03.025_bib35","doi-asserted-by":"crossref","DOI":"10.3389\/fnmol.2023.1258823","article-title":"Type 2 cytokines sensitize human sensory neurons to itch-associated stimuli","volume":"16","author":"Mack","year":"2023","journal-title":"Front Mol Neurosci"}],"container-title":["JAAD International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666328724000683?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666328724000683?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T22:59:47Z","timestamp":1740869987000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666328724000683"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":34,"alternative-id":["S2666328724000683"],"URL":"https:\/\/doi.org\/10.1016\/j.jdin.2024.03.025","relation":{},"ISSN":["2666-3287"],"issn-type":[{"value":"2666-3287","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dupilumab improves pruritus and skin lesions in patients with prurigo nodularis: Pooled results from 2 phase 3 trials (LIBERTY-PN PRIME and PRIME2)","name":"articletitle","label":"Article Title"},{"value":"JAAD International","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jdin.2024.03.025","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 by the American Academy of Dermatology, Inc. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}